SCHEMBL4058499

SCHEMBL4058499

CC(C)Oc1ccc2c(c1)c([C@@H]1CCN(C)C1)c1n2S(=O)(=O)c2ccccc2-1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.42
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
BRD4 O60885 1/20 0.33
BRPF1 P55201 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR1E P28566 1/20 0.33
HTR7 P34969 1/20 0.33
HTR2B P41595 1/20 0.33
HTR3A P46098 1/20 0.33
HTR5A P47898 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14177905 1.00 HTR6 (0.42) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4047804 1.00 HTR6 (0.42) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL5124488 0.90 HTR6 (0.42) HTR6ALDH1A1MAPTMAPK1HTR2A
SCHEMBL4049451 0.89 HTR6 (0.53) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL3324374 0.89 HTR6 (0.53) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4058308 0.89 HTR6 (0.53) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4048282 0.86 HTR6 (0.44) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4054154 0.86 HTR6 (0.44) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL14177900 0.86 HTR6 (0.44) HTR6CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4058810 0.86 HTR6 (0.41) HTR6CYP1A2CYP2C9CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1704154-B1 NOVEL INDENO [2,1A]INDENES AND ISOINDOL [2,1-A]INDOLES SUVEN LIFE SCIENCES LTD (IN) 2009-05-06 EP claimed
US-7388024-B2 Indeno[2,1A]indenes and isoindolo[2,1-A]indoles SUVEN LIFE SCIENCES LIMITED (IN) 2008-06-17 US claimed
US-20070054946-A1 Novel indeno[2,1A]indenes and isoindolo[2,1-A]indoles SUVEN LIFE SCIENCES LIMITED (IN) 2007-03-08 US claimed
EP-1704154-B1 NOVEL INDENO [2,1A]INDENES AND ISOINDOL [2,1-A]INDOLES SUVEN LIFE SCIENCES LTD (IN) 2009-05-06 EP disclosed
US-7388024-B2 Indeno[2,1A]indenes and isoindolo[2,1-A]indoles SUVEN LIFE SCIENCES LIMITED (IN) 2008-06-17 US disclosed
US-20070054946-A1 Novel indeno[2,1A]indenes and isoindolo[2,1-A]indoles SUVEN LIFE SCIENCES LIMITED (IN) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054946-A1 Novel indeno[2,1A]indenes and isoindolo[2,1-A]indoles IDO1, IDO2, OPRD1 HTR6 166/4885CYP1A2 17/4885CYP2C9 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.